Browsing Tag
AbbVie Inc.
12 posts
Phase 3 hepatitis C win fails to lift Atea stock against Gilead’s Epclusa
Atea’s eight-week hepatitis C regimen met Phase 3 endpoints against Epclusa, but $AVIR fell as investors questioned its commercial edge.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
AbbVie weighs $10.9bn Apogee deal to strengthen its next immunology growth cycle
AbbVie may pay $10.9 billion for Apogee Therapeutics before Phase 3. Read what the reported deal could mean for immunology growth and ABBV stock.
Can KST-6051 unlock broader KRAS cancer treatment beyond G12C inhibitors
KST-6051 enters Phase 1 with AbbVie Inc. backing. Discover how pan-KRAS inhibitors could expand treatment across KRAS-driven cancers.
AbbVie commits $380m to expand US drug manufacturing as supply chain control becomes strategic
AbbVie is investing $380 million to expand US drug manufacturing. Find out how this reshapes supply chains, margins, and long-term pharma strategy.
Can fixed-duration oral therapy finally replace indefinite CLL treatment? AstraZeneca’s FDA win explains why
FDA approval of AstraZeneca’s CALQUENCE plus venetoclax introduces a fixed-duration oral option for frontline CLL. Find out why this matters for patients and investors.
AbbVie Inc. (NYSE: ABBV) wins FDA approval for Venclexta and acalabrutinib in first-line chronic lymphocytic leukemia
AbbVie Inc. secures FDA approval for Venclexta plus acalabrutinib in first-line CLL. Find out why this decision matters for patients, payers, and investors.
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
Is bretisilocin the Cymbalta of psychedelic‑inspired psychiatry? What AbbVie’s $1.2 bn bet reveals
AbbVie’s $1.2 B deal for bretisilocin could signal the next era of antidepressants. Could this short‑acting compound become the Cymbalta of psychedelic‑inspired psychiatry?
Biologics race in Indian pharma: Can Glenmark’s AbbVie tie-up spark a broader innovation moment?
India’s biologics race heats up as Glenmark, Biocon, Sun Pharma, Dr. Reddy’s, and Lupin push beyond generics—see how each strategy stacks up.